Skip to Content
Merck

N1165

Pimonidazole

≥98% (HPLC),  2-nitroimidazole hypoxia marker, powder

Synonym(s):

NSC 380540, PD 126675;, Ro 03-8799;, alpha-((2-Nitroimidazol-1-yl)methyl)-1-piperidineethanol;, alpha-[(2-Nitro-1H-imidazol-1-yl)methyl]-1-piperidineethanol

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H18N4O3
CAS Number:
70132-50-2
Molecular Weight:
254.29
UNSPSC Code:
12352200
PubChem Substance ID:
329818508
NACRES:
NA.77
MDL number:
MFCD00867974

Product Name

Pimonidazole, ≥98% (HPLC)

SMILES string

OC(CN1CCCCC1)Cn2ccnc2[N+]([O-])=O

InChI key

WVWOOAYQYLJEFD-UHFFFAOYSA-N

InChI

1S/C11H18N4O3/c16-10(8-13-5-2-1-3-6-13)9-14-7-4-12-11(14)15(17)18/h4,7,10,16H,1-3,5-6,8-9H2

assay

≥98% (HPLC)

form

powder

color

yellow

solubility

DMSO: >20 mg/mL

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker.
Pimonidazole is an effective and nontoxic exogenous 2-nitroimidazole hypoxia marker. Pimonidazole forms adducts with thiol groups in proteins, peptides and amino acids.
Pimonidazole possesses a nitro group at position 2 and an imidazole ring. Pimonidazole undergoes reduction and is activated in hypoxic cells.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000518586
0000518586
0000455613
0000455613
0000295515

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lena-Christin Conradi et al.
Angiogenesis, 20(4), 599-613 (2017-09-07)
Blockade of the glycolytic activator PFKFB3 in cancer cells (using a maximum tolerable dose of 70 mg/kg of the PFKFB3 blocker 3PO) inhibits tumor growth in preclinical models and is currently being tested as a novel anticancer treatment in phase I
Hypoxia Studies with Pimonidazole in vivo
Aguilera KY and Brekken RA
Bio-protocol, 4(19) (2014)
Yong Chen et al.
Disease models & mechanisms, 12(12) (2019-11-11)
Major risk factors for necrotizing enterocolitis (NEC) are formula feeding and prematurity; however, their pathogenic mechanisms are unknown. Here, we found that insufficient arginine/nitric oxide synthesis limits blood flow in the intestinal microvasculature, leading to hypoxia, mucosal damage and NEC
Loren P Thompson et al.
Biology of reproduction, 95(6), 128-128 (2016-11-04)
Chronic placental hypoxia is one of the root causes of placental insufficiencies that result in pre-eclampsia and maternal hypertension. Chronic hypoxia causes disruption of trophoblast (TB) development, invasion into maternal decidua, and remodeling of maternal spiral arteries. The pregnant guinea
Laura Parma et al.
Cells, 9(2) (2020-02-07)
Unstable atherosclerotic plaques frequently show plaque angiogenesis which increases the chance of rupture and thrombus formation leading to infarctions. Hypoxia plays a role in angiogenesis and inflammation, two processes involved in the pathogenesis of atherosclerosis. We aim to study the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service